Eli Lilly: 6,000 jobs for Houston and mega investments by 2031!

Eli Lilly: 6,000 jobs for Houston and mega investments by 2031!

Eli Lilly has significantly advanced its growth strategy in the production and development of new medicines. The company has invested over $50 billion in new manufacturing facilities in the US since 2020 to significantly expand its capacity. The latest and largest investment includes $5.9 billion for a new active ingredient (API) facility in Houston, scheduled to begin production in 2031. These new facilities are intended not only to reduce the dependency on global supply chains, but also to form a basis for future growth.

The new Houston facility is expected to create 600 permanent jobs, while approximately 10,000 jobs will be created during the construction phase. Three of the four new production sites in the US focus on the production of active pharmaceutical ingredients, while the fourth specializes in injectable medications. Eli Lilly has also accelerated its expansion in India, where the diabetes and obesity drug Mounjaro has been available since March 2025.

Strong sales growth and forecasts for 2025

In the fourth quarter of 2024, Eli Lilly doubled its profit to $4.41 billion, driven by increased sales of diabetes and obesity treatments. Sales of diabetes drug Mounjaro rose 60% to $3.53 billion, while obesity drug Zepbound generated $1.9 billion in the same quarter. Overall, total revenue was $13.53 billion, up 45% year-on-year and in line with market expectations.

Earnings per share of $5.32 were above forecasts of $5.01. Mounjaro and Zepbound, both GLP-1 receptor agonists, are growing in popularity in the weight loss space and compete directly with Novo Nordisk's products, which also have strong sales. For 2024, Mounjaro sales saw an increase to $11.54 billion, while Zepbound brought in $4.9 billion in its first full year.

Future developments and challenges

For 2025, Eli Lilly expects adjusted earnings of between $22.50 and $24 per share on total sales of $58 billion to $61 billion. Analysts expect earnings of $22.77 per share and revenue of $58.8 billion. Eli Lilly's stock price rose about 2% to $857.40, and the stock's value has increased 9% since the beginning of the year.

Despite these positive developments, there remains a certain degree of uncertainty about the implementation of investments in sustainable growth. Institutional investors are showing different reactions to current financial data and strategies. Versant Capital increased its position by 68%, while Summit Global Investments reduced its stake by 19%.

In the coming months, Eli Lilly will take part in two major specialist conferences. At the ASCO Annual Meeting, the company will present trial data for its cancer drugs imlunestrant and olomorasib. In addition, results on tirzepatide (Zepbound, Mounjaro) and retatrutide are expected at the ADA Scientific Sessions, which could further strengthen the company's position in the diabetes portfolio.

In summary, Eli Lilly's significant investments and strategic developments in both production and revenue growth position it well to continue to operate successfully in the coming years. The Stock World reports in detail on these positive trends, while AP News provides detailed financial reports and forecasts.